Antioxidant And Anti-aging Potential Of A Peptide Formulation (Gal2–Pep) Conjugated With Gallic Acid Ⅱ

May 04, 2023

3. Results and discussion

3.1. Synthesis and conjugation of gallic acid with peptide 

The synthesized peptides TPPTTP, galloyl–TPPTTP (Gal–Pep), and Gal2–Pep were obtained and purified using semi-preparative RP-HPLC. Fig. 1a and Scheme 1 show the conjugation strategy of gallic acid with KTPPTTP as Gal2–Pep. In the SPPS method, the impurities generated during peptide synthesis usually include side-reacted peptides, amino acid-protecting groups, and solvents used for synthesis and purification. The HOBt used in peptide synthesis is known to inhibit racemization and improve the efficiency of peptide synthesis.17–19 In order to remove amino acid-protecting groups and solvents used for synthesis, we performed washing several times using solvents such as DMF and DCM during the peptide synthesis process. Even after the last washing step, impurities including amino acid-protecting groups are still present in trace amounts. In order to meet the peptide purity of more than 90% reported by several researchers,20–22 semi-prep HPLC was performed as a polishing step to obtain the nal peptide of 99.2% purity as a result of HPLC analysis (see Fig. S1†). The purified peptide product was analyzed using Q-TOF to reconfirm their successful synthesis (Fig. 1b–d).

KSL11

Click Here To Get More Info About Cistanche Treat Anti-Aging


3.2. Cell viability assays

To investigate the cytotoxicity of the synthesized peptides, HaCaT, and human dermal fibroblast cells were treated with various concentrations of GA, TPPTTP, Gal–Pep, and Gal2–Pep for 24 h and analyzed using CCK-8 assays. It was confirmed that the synthesized peptides had no toxic effect on the treated cells, with cell viability of at least 88% for all samples and all the concentrations tested (Fig. 2a and b), indicating that TPPTTP, GalPep, and Gal2Pep is suitable for use in cosmetics applications. Additionally, it was confirmed by MTT, LDH, and Griess reagent assay that the nal peptide did not cause toxicity in HA and F and inflammatory response in raw 264.7. (Fig. S2S4).



3.3. Antioxidant activity of synthesized peptides

The mechanisms involved in skin aging include ROS activity, mitochondrial DNA mutations, the shortening of telomeres, and hormonal changes, particularly in women.23 ROS act as cell signaling molecules for many cellular processes, such as differentiation and proliferation.24 However, excessive ROS can lead to the cleavage and abnormal binding of collagen and elastin chains and increase the expression of MMP-1, an enzyme that breaks down collagen, thus accelerating aging and cell apoptosis. Therefore, it is important to remove ROS from skin cells to promote anti-aging effects. In this study, we confirmed the antioxidant activity of the synthesized peptides through DPPH and DCF-DA assays. Fig. 3a presents the results of the radical scavenging activity of the synthesized peptides as measured using DPPH assay. 

TPPTTP had no radical scavenging activity at any concentration, while GA, Gal–Pep, and Gal2–Pep exhibited higher radical scavenging activity in a concentration-dependent manner.

KSL02

In particular, Gal2Pep demonstrated the most effective antioxidant activity; at a concentration of 10 mM, GA, GalPep, and Gal2Pep had a radical scavenging activity of 13.6%, 24.23%, and 26.0%, respectively. This indicates that the binding of TPPTTP to GA does not inhibit the radical scavenging activity. Fig. 3b confirms the stability of the samples as confirmed by assessing their radical scavenging activity when stored at room temperature. GA retained its radical scavenging activity for up to one week but, after two weeks, this activity decreased by more than 60%. On the other hand, GalPep and Gal2Pep maintained their scavenging activity for over two weeks. In particular, Gal2Pep had a radical scavenging activity of 50% even in its fourth week. These results suggest that binding GA to TPPTTP stabilizes its radical scavenging activity. Some studies have shown that ascorbic acid is stabilized by binding it with peptides.12,25 We believe that GA may be stabilized by binding it with a peptide in the same way.


The antioxidant effect of the peptides was also tested using DCFDA assays in the presence of intracellular oxidative stress induced by H2O2 (Fig. 4). Aer 24 h of treating the samples on the cells at a concentration of 100 mM, DCF-DA was loaded onto the cells, and the cells were then treated with H2O2 for 30 min and the fluorescence intensity of DCF was observed at an excitation wavelength of 485 nm and an emission wavelength of 535 nm. Cells subjected to oxidative stress with 1 mM H2O2 exhibited fluorescence intensity that was more than three times higher than the negative control; however, Gal2–Pep treatment produced a fluorescence that was only 67% of that produced by cells treated with H2O2 only. In the presence of TPPTTP, which did not exhibit radical scavenging activity (Fig. 3a), the ROS stress caused by H2O2 was reduced by about 20%, supporting previous research that has reported that TPPTTP decreases ROS levels in cells.24 When the cells were treated with GA only, there was no significant change in ROS levels. Taken together, these results suggest that Gal2–Pep, which combines two GA molecules with a peptide, is a stable and effective antioxidant.



3.4. Effect of synthesized peptides on the mitochondria membrane potential

In this study, JC-1 dye was used to investigate the effect of the synthesized peptides on the MmP (DJm). The MmP acts as an important parameter for mitochondrial function and is known to be associated with several diseases such as Alzheimer's and Huntington's disease.26 JC-1 dye produces a redshirt from green emissions by accumulating in mitochondria and forming J-aggregates. After treating the HaCaT and fibroblast cells with the synthesized peptides for 24 h, the cells were exposed to JC-1 dye for 10 min, and then the fluorescence intensity was measured using a microplate reader (green lEx ¼ 475 nm and lEm ¼ 530 nm, red lEx ¼ 475 nm and lEm ¼ 590 nm). The ratio of the red to green fluorescence was expressed as the fold-change compared to the negative control (Fig. 5). HaCaT cells treated with GA and the peptide independently did not exhibit any significant change compared to the negative control group, while Gal2–Pep exhibited a significant difference, increasing 1.45-fold compared to the control. The fibroblast cells treated with Gal2–Pep also significantly

increased 1.12-fold compared to the negative control. The increase in MmP with Gal2–Pep treatment clearly indicates that Gal2–Pep is a biomolecule that can be employed in anti-aging cosmetics.


cistanche anti-aging


Fig. 4 Intracellular antioxidant activity assays using DCF-DA at gallic acid and peptide concentrations of 100 mM. After 24 hours of treatment, H2O2 was added and incubated for 30 minutes, followed by measurement of DCF fluorescence intensity. Asterisks indicate statistically significant differences (*p < 0.05, **p < 0.005, ***p < 0.001).


cistanche anti-aging


Fig. 5 Measurement of the mitochondrial membrane potential using JC-1 dye in (a) HaCaT cells and (b) dermal fibroblasts. Asterisks indicate statistically signifificant differences (*p < 0.05, **p < 0.005, ***p <0.001)


cistanche anti-aging


Fig. 6 Measurement of the elastase activity in dermal fibroblasts at gallic acid and peptide concentrations of 100 mM. Asterisks indicate statistically significant differences (*p < 0.05, **p < 0.005, ***p < 0.001).



3.5. Elastase inhibitory activity

Elastase promotes skin aging by breaking down collagen or elastin in the skin, so it can prevent skin aging by inhibiting elastase.27 Fig. 6 shows elastase activity in CCD-1064Sk cells treated with each sample. TPPTTP has a rare effect on elastase inhibition. However, treatment with gallic acid, GalPep, and Gal2Pep showed elastase activity by 69%, 84% and 76%, respectively. Gal2Pep inhibited elastase by 7% less than that of GA. However, when considering the results of measurement of antioxidant effect, long-term stability, and mitochondrial membrane potential, Gal2Pep was more effective than GA as an anti-aging agent.

cistanche anti-aging

3.6. Expression of type I collagen, MMP-1, and PGC-1a genes

Fig. 7 shows RT-qPCR data of type I collagen, MMP-1, and PGC-1a gene expression. Type I collagen, a major component of the collagen family found within the skin, decreases as aging progresses.28 When Gal2Pep was used to treat fibroblasts for 8 h and 24 h, the expression of type I collagen increased approximately 1.19- and 1.21-fold, respectively. With GA and GalPep, there was no significant change after 2 h and 8 h, but type I collagen expression increased 1.16- and 1.26-fold after 24 h, respectively. With TTPTTP treatment, however, expression increased by 1.24-fold in the first 2 h and then gradually decreased. After 24 h, the expression level was similar to that of the negative control (Fig. 7a). For MMP-1, expression levels of 0.43, 0.44, and 0.68-fold were observed after 24 h with GA, GalPep, and Gal2Pep treatment, respectively. In addition, the expression levels with GA treatment increased by 1.46-fold after 2 h. With TPPTTP, MMP-1 expression decreased 0.87-fold after 2h, but subsequently became similar to that of the negative control. Overall, restoring collagen levels, which otherwise decreases with aging, helps to improve wrinkles.28



image

cistanche anti-aging

Fig. 7 Gene expression analysis in dermal fibroblasts using RT-qPCR: (a) type I collagen, (b) MMP-1, and (c) PGC-1a.



The expression of PGC-1a was highest after 8 h for all treatments, with expression rates for GA, TPPTTP, Gal–Pep, and Gal2–Pep increasing 2.06-, 1.41-, 1.07-, and 2.05-fold, respectively. However, unlike the other treatments, Gal2–Pep increased PGC-1a expression 1.27-fold after 24 h. PGC-1a regulates the synthesis and antioxidant effects of mitochondria and is reported to decrease with aging.29–32 Therefore, Gal2–Pep has the potential to be used as an effective antioxidant that can effectively protect against ROS. 

Taken all together, Gal2–Pep increased the expression of PGC-1a and collagen compared to the effects of GA and TPPTTP alone, while the expression of MMP-1 tended to decrease, thus illustrating its potential for use in anti-aging cosmetics

KSL26


4. Conclusion

In this study, Gal2–Pep, which was developed by combining GA and the peptide TPPTTP, exhibited excellent antioxidant activity and mitochondrial activation in skin cells. The cell viability results clearly indicated that Gal2–Pep has no cytotoxic effect on skin cells. Gal2–Pep also demonstrated dose-dependent antioxidant and free radical scavenging activity, with ROS scavenging activity over 50% even after storage for four weeks at room temperature. It also positively influenced the MmP and increased the expression of PGC-1a, which regulates the mitochondrial synthesis and has an antioxidant effect by eliminating free radicals within the skin. Gal2Pep also increased the expression of type I collagen and decreased elastase activity and the expression of MMP-1, proving that it holds promise for use in anti-aging cosmetics.


Conflicts of interest

There are no conflicts to declare.


Acknowledgments

This study was supported by a grant of the Korea Industrial Complex Corp. (KICOX, NTIS No. 1415165722) and the Inha University Research Grant.



References

1 P. Brenneisen, H. Sies and K. Scharffffetter-Kochanek, Ann. N.Y. Acad. Sci., 2002, 973, 31–43.
2 A. Trifunovic, A. Wredenberg, M. Falkenberg, J. N. Spelbrink,A. T. Rovio, C. E. Bruder, M. Bohlooly-Y, S. Gldl ¨of, A. Oldfors,R. Wibom, J. T¨ornell, H. T. Jacobs and N. G. Larsson,
Nature,2004, 429, 417–423.
3 S. B. Khan, C. S. Kong, J. A. Kim and S. K. Kim, Biotechnol. Bioprocess Eng., 2010, 15, 191–198.
4 H.-J. Kim, K.-W. Kim, B.-P. Yu and H.-Y. Chung, Free Radical Biol. Med., 2000, 28, 683–692.
5 M. Erden Inal, A. Kahraman and T. Koken,Clin. Exp.Dermatol., 2001, 26, 536–539.
6 H. S. Jin, S. Y. Park, J. Y. Kim, J. E. Lee, H. S. Lee, N. J. Kang and D. W. Lee, Biotechnol. Bioprocess Eng., 2019, 24, 240–249.
7 H. Masaki, J. Dermatol. Sci., 2010, 58, 85–90.
8 T. S. A. Thring, P. Hili and D. P. Naughton, BMC Complementary Altern. Med., 2009, 9, 27.
9 L. Quiles-Carrillo, S. Montava-Jord a, T. Boronat, C. Sammon, R. Balart and S. Torres-Giner, Polymers, 2019, 12, 31. 10 D. H. Park, D. H. Jung, S. J. Kim, S. H. Kim and K. M. Park,
BMC Biochem., 2014, 15, 4–10.
11 Y. J. Cheng, G. F. Luo, J. Y. Zhu, X. D. Xu, X. Zeng, D. B. Cheng, Y. M. Li, Y. Wu, X. Z. Zhang, R. X. Zhuo and F. He, ACS Appl. Mater. Interfaces, 2015, 7, 9078–9087.
12 H. Lee, A. T. E. Vilian, J. Y. Kim, M. H. Chun, J. S. Suh,H. H. Seo, S. H. Cho, I. S. Shin, S. J. Kim, S. H. Park,Y.-K. Han, J. H. Lee and Y. S. Huh, RSC Adv., 2017, (48), 30205–30213.
13 Y. Kong, C. Xu, Z. L. He, Q. M. Zhou, J. Bin Wang, Z. Y. Li and X. Ming, Peptides, 2014, 53, 70–78.
14 H. Kim, J. S. Kim, Y. G. Kim, Y. Jeong, J. E. Kim, N. S. Paek and C. H. Kang, Biotechnol. Bioprocess Eng., 2020, 25, 421–430.
15 M. A. Frezzini, F. Castellani, N. De Francesco, M. Ristorini and S. Canepari, Atmosphere, 2019, 10(12), DOI: 10.3390/atmos10120816.
16 A. Rengaraj, P. Puthiaraj, N. S. Heo, H. Lee, S. K. Hwang,S. Kwon, W. S. Ahn and Y. S. Huh, Colloids Surf., B, 2017,160, 1–10.
17 T. Miyazawa, T. Otomatsu, Y. Fukui, T. Yamada and S. Kuwata, J. Chem. Soc., Chem. Commun., 1988, 419–420.
18 S. M. Mali, M. Ganesh Kumar, M. M. Katariya and H. N. Gopi, Org. Biomol. Chem., 2014, 12, 8462–8472. 19 T. Michels, R. D ¨olling, U. Haberkorn and W. Mier, Org. Lett., 2012, 14, 5218–5221.

20 P. Song, W. Du, W. Li, L. Zhu, W. Zhang, X. Gao, Y. Tao and F. Ge, Nanomater. Nanotechnol., 2020, 10, 1–10. 

21 M. De Zotti, B. Biondi, Y. Park, K.-S. Hahm, M. Crisma, C. Toniolo and F. Formaggio, Amino Acids, 2012, 43, 1761–1777.

22 Z. Zhai, K. Xu, L. Mei, C. Wu, J. Liu, Z. Liu, L. Wan and W. Zhong, So Matter, 2019, 15, 8603–8610.

23 D. J. Tobin, J. Tissue Viability, 2017, 26, 37–46.

24 M. Schieber and N. S. Chandel, Curr. Biol., 2014, 24, 453–462.

















You Might Also Like